Eli Lilly har skutt opp i mega-cap-territorium drevet av sine revolusjonerende GLP-1 diabetes- og fedmemidler Mounjaro og Zepbound, som representerer en av de største farmasøytiske mulighetene på tiår.
Eli Lilly er en dominerende farmasøytisk aksje som surfer på den enestående kommersielle suksessen av sine GLP-1-terapier Mounjaro og Zepbound, som har posisjonert selskapet i forkant av revolusjonene innen fedmebehandling og gjort det til et av de høyest verdsatte farmasøytiske selskapene i historien.
Eli Lilly har blitt ett av verdens mest verdifulle selskaper drevet av sine GLP-1 vekttaps- og diabetesmidler Mounjaro og Zepbound, og leder fedmebehandlingsrevolusjonen.
Data updated Feb 15 · Source: Twelve Data
Eli Lilly has emerged as one of the most compelling stories in pharma, driven primarily by its blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and weight loss. The stock's 415% five-year return reflects extraordinary investor enthusiasm for its pipeline and commercial execution.
The bull case is powerful: Lilly dominates the rapidly expanding weight management market alongside Novo Nordisk, with a potentially superior efficacy profile. Its broader pipeline spanning Alzheimer's (donanemab), immunology, and oncology provides diversification beyond GLP-1s. Revenue growth has been exceptional as manufacturing scales.
However, the valuation demands scrutiny. A P/E of 54.7x prices in years of flawless execution. Key risks include potential GLP-1 competition from oral alternatives, pricing pressure from government negotiations, and manufacturing capacity constraints. The stock trading ~8% below its 52-week high suggests some investor caution has crept in.
EPS of $19.00 TTM reflects strong profitability, but investors must weigh whether the premium valuation adequately accounts for execution risk. For long-term investors with conviction in the obesity treatment megatrend, Lilly remains best-in-class, though entry timing matters at these levels.
Eli Lilly has established itself as the premier growth story in the pharmaceutical sector, driven primarily by the unprecedented demand for its GLP-1 agonists, Mounjaro and Zepbound. Trading near $1,025, the stock commands a premium valuation with a P/E ratio of roughly 54, significantly higher than industry peers. However, this multiple reflects the massive earnings potential of its obesity and diabetes portfolio, alongside a promising pipeline that includes treatments for Alzheimer's disease. While the company faces challenges regarding manufacturing capacity to meet soaring demand and stiff competition from Novo Nordisk, its financial health remains robust with a TTM EPS of $19.00. For investors, LLY represents a high-conviction growth play, though the current price point requires confidence that the company can flawlessly execute its production ramp-up and maintain pricing power.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Hver trader har en strategi som ser flott ut i hodet deres. Backtesting er hvordan du finner ut om den faktisk fungerer. Her er hvordan du tester strategier på riktig måte, hvilke beregninger som betyr noe, og hvorfor de fleste backtestresultater er for gode til å være sant.
Powered by Rexiew